Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 95

1.

Enhanced growth of influenza vaccine seed viruses in vero cells mediated by broadening the optimal pH range for virus membrane fusion.

Murakami S, Horimoto T, Ito M, Takano R, Katsura H, Shimojima M, Kawaoka Y.

J Virol. 2012 Feb;86(3):1405-10. doi: 10.1128/JVI.06009-11. Epub 2011 Nov 16.

2.
3.

A Vero-cell-adapted vaccine donor strain of influenza A virus generated by serial passages.

Hu W, Zhang H, Han Q, Li L, Chen Y, Xia N, Chen Z, Shu Y, Xu K, Sun B.

Vaccine. 2015 Jan 3;33(2):374-81. doi: 10.1016/j.vaccine.2014.11.007. Epub 2014 Nov 18.

PMID:
25448099
4.

A cell-based backup to speed up pandemic influenza vaccine production.

Lee MS, Hu AY.

Trends Microbiol. 2012 Mar;20(3):103-5. doi: 10.1016/j.tim.2011.12.002. Epub 2012 Jan 16.

PMID:
22257962
5.

Generation of high-yielding influenza A viruses in African green monkey kidney (Vero) cells by reverse genetics.

Ozaki H, Govorkova EA, Li C, Xiong X, Webster RG, Webby RJ.

J Virol. 2004 Feb;78(4):1851-7.

6.

Preflucel®: a Vero-cell culture-derived trivalent influenza vaccine.

Chan CY, Tambyah PA.

Expert Rev Vaccines. 2012 Jul;11(7):759-73. doi: 10.1586/erv.12.55. Review.

PMID:
22913252
7.

Development of high-yield influenza A virus vaccine viruses.

Ping J, Lopes TJ, Nidom CA, Ghedin E, Macken CA, Fitch A, Imai M, Maher EA, Neumann G, Kawaoka Y.

Nat Commun. 2015 Sep 2;6:8148. doi: 10.1038/ncomms9148.

8.

Impact of host cell line adaptation on quasispecies composition and glycosylation of influenza A virus hemagglutinin.

Roedig JV, Rapp E, Höper D, Genzel Y, Reichl U.

PLoS One. 2011;6(12):e27989. doi: 10.1371/journal.pone.0027989. Epub 2011 Dec 7.

9.

Live cold-adapted influenza A vaccine produced in Vero cell line.

Romanova J, Katinger D, Ferko B, Vcelar B, Sereinig S, Kuznetsov O, Stukova M, Erofeeva M, Kiselev O, Katinger H, Egorov A.

Virus Res. 2004 Jul;103(1-2):187-93.

PMID:
15163508
10.

Adaptation of high-growth influenza H5N1 vaccine virus in Vero cells: implications for pandemic preparedness.

Tseng YF, Hu AY, Huang ML, Yeh WZ, Weng TC, Chen YS, Chong P, Lee MS.

PLoS One. 2011;6(10):e24057. doi: 10.1371/journal.pone.0024057. Epub 2011 Oct 13.

11.

African green monkey kidney (Vero) cells provide an alternative host cell system for influenza A and B viruses.

Govorkova EA, Murti G, Meignier B, de Taisne C, Webster RG.

J Virol. 1996 Aug;70(8):5519-24.

12.

Egg- or cell culture-derived hemagglutinin mutations impair virus stability and antigen content of inactivated influenza vaccines.

Nakowitsch S, Waltenberger AM, Wressnigg N, Ferstl N, Triendl A, Kiefmann B, Montomoli E, Lapini G, Sergeeva M, Muster T, Romanova JR.

Biotechnol J. 2014 Mar;9(3):405-14. doi: 10.1002/biot.201300225. Epub 2013 Dec 10. Erratum in: Biotechnol J. 2014 Apr;9(4):585.

PMID:
24323790
13.

Serum-free microcarrier based production of replication deficient influenza vaccine candidate virus lacking NS1 using Vero cells.

Chen A, Poh SL, Dietzsch C, Roethl E, Yan ML, Ng SK.

BMC Biotechnol. 2011 Aug 11;11:81. doi: 10.1186/1472-6750-11-81.

14.

Establishment of Vero cell RNA polymerase I-driven reverse genetics for Influenza A virus and its application for pandemic (H1N1) 2009 influenza virus vaccine production.

Song MS, Baek YH, Pascua PN, Kwon HI, Park SJ, Kim EH, Lim GJ, Choi YK.

J Gen Virol. 2013 Jun;94(Pt 6):1230-5. doi: 10.1099/vir.0.051284-0. Epub 2013 Mar 13.

PMID:
23486669
15.

Use of MDCK cells for production of live attenuated influenza vaccine.

Liu J, Shi X, Schwartz R, Kemble G.

Vaccine. 2009 Oct 30;27(46):6460-3. doi: 10.1016/j.vaccine.2009.06.024. Epub 2009 Jun 24.

PMID:
19559113
16.

A single NS2 mutation of K86R promotes PR8 vaccine donor virus growth in Vero cells.

Zhang H, Han Q, Ping X, Li L, Chang C, Chen Z, Shu Y, Xu K, Sun B.

Virology. 2015 Aug;482:32-40. doi: 10.1016/j.virol.2015.03.004. Epub 2015 Mar 26.

17.

Development of a Vero cell-derived influenza whole virus vaccine.

Kistner O, Barrett PN, Mundt W, Reiter M, Schober-Bendixen S, Eder G, Dorner F.

Dev Biol Stand. 1999;98:101-10; discussion 111.

PMID:
10494963
18.

Influenza hemagglutinin (HA) stem region mutations that stabilize or destabilize the structure of multiple HA subtypes.

Byrd-Leotis L, Galloway SE, Agbogu E, Steinhauer DA.

J Virol. 2015 Apr;89(8):4504-16. doi: 10.1128/JVI.00057-15. Epub 2015 Feb 4.

19.

Growth and immunogenicity of influenza viruses cultivated in Vero or MDCK cells and in embryonated chicken eggs.

Govorkova EA, Kodihalli S, Alymova IV, Fanget B, Webster RG.

Dev Biol Stand. 1999;98:39-51; discussion 73-4.

PMID:
10494958
20.

Nonreplicating vaccinia virus vectors expressing the H5 influenza virus hemagglutinin produced in modified Vero cells induce robust protection.

Mayrhofer J, Coulibaly S, Hessel A, Holzer GW, Schwendinger M, Brühl P, Gerencer M, Crowe BA, Shuo S, Hong W, Tan YJ, Dietrich B, Sabarth N, Savidis-Dacho H, Kistner O, Barrett PN, Falkner FG.

J Virol. 2009 May;83(10):5192-203. doi: 10.1128/JVI.02081-08. Epub 2009 Mar 11.

Supplemental Content

Support Center